ImmunoGen, Inc. (NASDAQ:IMGN)

CAPS Rating: 3 out of 5

The Company develops antibody-based anticancer therapeutics.

Results 1 - 20 of 43 : 1 2 3 Next »

Recs

0
Member Avatar JimmyLocos (48.60) Submitted: 6/12/2015 9:00:09 AM : Outperform Start Price: $14.11 IMGN Score: +25.56

Great platform to generate money from other peoples success. The have learned how to monetize their tech, some interesting drugs in their own pipeline, looks pretty solid in the LONG LONG LONG run.

Recs

0
Member Avatar infinitesimal (62.92) Submitted: 6/6/2015 2:38:25 PM : Outperform Start Price: $12.82 IMGN Score: +26.29

After the disappointment with Phase3-Marianne trial in 1st line HER2neu positive breast cancer and drug Kadcyla, IMGN just showed at ASCO with their new experimental drug for platinum-resistant ovarian cancer that the idea of pairing an antibody with a zytotoxic drug is working (proof of concept again). As they seem to have a lot of knowledge and patents in this, there might be more successful drugs in the future.
Sooner or later one will come through, hopefully.
Still long IMGN.

Recs

0
Member Avatar joienpaix (25.29) Submitted: 3/18/2015 7:45:09 PM : Outperform Start Price: $7.59 IMGN Score: +133.00

Wait for it to recover.

Recs

0
Member Avatar ayacullo (< 20) Submitted: 12/29/2014 11:42:14 AM : Outperform Start Price: $6.11 IMGN Score: +188.75

immunogen may have had it rough at the end of 2014 but still has many promising therapies for various types of cancers including NHL. Compared to big ticket biotech stocks, this one is a buy at 6.93 - - I see a 12 month target at 14.00
- I like the options too!

Recs

0
Member Avatar hba24 (95.00) Submitted: 12/19/2014 2:24:49 PM : Outperform Start Price: $6.35 IMGN Score: +176.86

Dip provides a good entry point.

Recs

0
Member Avatar benyboy (< 20) Submitted: 9/8/2014 11:56:51 PM : Outperform Start Price: $11.64 IMGN Score: +47.08

see a lot of value here, said Cramer. At current levels I'm a buyer

Recs

0
Member Avatar asilverp (32.82) Submitted: 8/29/2014 11:29:20 PM : Underperform Start Price: $12.02 IMGN Score: -42.57

High valuations and low relative strength. Will probably continue to slide.

Recs

0
Member Avatar gkm2864 (< 20) Submitted: 2/6/2014 3:58:36 PM : Outperform Start Price: $14.33 IMGN Score: +4.97

Big pipeline of potentially profitable new drugs.

Recs

0
Member Avatar jb2un (36.77) Submitted: 1/3/2014 4:29:58 PM : Outperform Start Price: $14.63 IMGN Score: +5.96

I am hoping for a big year with clinical trials and partnered products.

Recs

0
Member Avatar TerryHoodSr (77.27) Submitted: 10/30/2013 2:45:53 PM : Outperform Start Price: $13.83 IMGN Score: +8.46

1yr sales grwth 117% ,3yr sales grwth 33%

Recs

0
Member Avatar Sagemanx (57.99) Submitted: 8/15/2013 3:34:11 AM : Outperform Start Price: $16.61 IMGN Score: -19.11

UBS must be trying to drive this down, don't fall for it...

Recs

0
Member Avatar DrLinks (< 20) Submitted: 7/20/2013 4:27:53 PM : Outperform Start Price: $18.84 IMGN Score: -30.24

With its AntiSense technology, this is a Biotech winner LT!

Recs

0
Member Avatar ElRemaro (34.58) Submitted: 3/31/2013 10:00:34 AM : Outperform Start Price: $16.02 IMGN Score: -23.87

TMFUltraLong

Recs

0
Member Avatar bychen (< 20) Submitted: 1/22/2013 11:11:45 AM : Outperform Start Price: $15.68 IMGN Score: -29.03

The technology is bearing fruit and could be applied to multiple cancers.

Recs

0
Member Avatar Agabone (< 20) Submitted: 1/14/2013 8:22:35 PM : Outperform Start Price: $14.65 IMGN Score: -23.00

Immunogen's proprietary TAP technology is licensedto Genentech for their groundbreaking drug for HER2-positive metastatic breast cancer. This drug looks all set for approval within the very near future and its clinical trials data show significant increases in overall survival. This is a treatment that has the potential to transform the eway we treat breast cancer and has implications for other tumor types, too. When the drug is approved, the money will start to roll in for Immunogen.

Recs

0
Member Avatar genedom (98.53) Submitted: 10/30/2012 2:18:55 AM : Outperform Start Price: $11.52 IMGN Score: +5.33

Value at this price.

Recs

0
Member Avatar HIGHG33K (95.40) Submitted: 9/13/2012 11:22:15 AM : Outperform Start Price: $14.56 IMGN Score: -24.01

Undervalued comparing with SGEN

Recs

0
Member Avatar etbean (57.97) Submitted: 8/7/2012 4:20:44 PM : Outperform Start Price: $13.10 IMGN Score: -15.33

just watching it go down. Will buy around 8$

Recs

0
Member Avatar talia123 (57.41) Submitted: 3/30/2012 9:44:05 AM : Outperform Start Price: $15.06 IMGN Score: -32.09

It only take 1 good drug

Recs

0
Member Avatar kmv98finance (55.12) Submitted: 1/31/2012 12:56:29 PM : Outperform Start Price: $14.14 IMGN Score: -35.40

This is a great company based on a solid science foundation. It's platform is proving to work. Not only did TDM1 have phenomenal phase 2 results, but its partnerships with other companies are also doing very well. This indicates a lot more future value when these products get through development. I see this as a buy and anticipate the company will be acquired someday...hopefully by Roche.

Results 1 - 20 of 43 : 1 2 3 Next »

Featured Broker Partners


Advertisement